|
dermatological reactions at injection sites |
|
dermatological reactions at injection sites |
|
|
anemia and hypoalbuminemia |
|
|
|
injection site reactions |
OAE:0000336
|
|
edema of the extremities |
OAE:0000389
|
|
varicella vaccine meningitis |
OAE:0000359
OAE:0000
|
|
diabetic ketoacidosis |
OAE:0002494
|
|
usual type vulvar intraepithelial neoplasia |
|
|
erythematous and indurated pruritic rash |
OAE:0001358
OAE:0001
|
|
injection site reactions |
OAE:0000045
|
|
eosinophilic pneumonia |
OAE:0008826
|
|
influenza-like symptoms |
OAE:0000100
|
|
anaphylactic reactions |
OAE:0000568
|
|
hematologic toxicities |
|
|
fatigue |
OAE:0000034
|
|
fever |
OAE:0000361
|
|
gastrointestinal symptoms |
OAE:0000975
OAE:0000
|
|
elevation of hepatic enzymes |
OAE:0001025
|
|
hypoalbuminemia |
OAE:0001054
|
|
leukocytopenia |
OAE:0000380
|
|
neutropenia |
OAE:0001217
|
|
hepatic-andbiliary tract infection |
OAE:0000210
OAE:0005
|
|
nausea |
OAE:0000600
|
|
increased AST |
|
|
vaccination site pruritus |
OAE:0006891
|
|
erythema |
OAE:0000645
|
|
headache |
OAE:0000377
|
|
Allergic reaction |
OAE:0000568
|
|
Dizziness |
OAE:0000388
|
|
Dyspnea |
OAE:0000310
|
|
Injection site reaction |
OAE:0000045
|
|
Peripheral sensory neuropathy |
OAE:0001288
|
|
Rash |
OAE:0000362
|
|
Skin hyperpigmentation |
OAE:0001397
|
|
Vaccine-induced thrombocytopenia with thrombosis |
OAE:000540
|
|
chills |
OAE:0000394
|
|
convulsions |
OAE:0007926
|
|
injection-site reaction |
OAE:0000045
|
|
flu-like symptoms |
OAE:0000399
|
|
diarrhea |
OAE:0000616
|
|
lymphopaenia |
|
|
neutropaenia |
OAE:0001217
|
|
leukopaenia |
OAE:0001129
|
|
eosinophilia |
OAE:0000920
|
|
thrombocytopaenia |
OAE:0001448
|
|
decreased appetite |
OAE:0000396
|
|
myalgia |
OAE:0000375
|
|
injection site erythema |
OAE:0004524
|
|
injection site induration |
OAE:0000323
|
|
aspartate aminotransferase increase |
OAE:0000656
|
|
blood alkaline phosphatase increase |
OAE:0000720
|
|
lung infection |
OAE:0001144
|
|
a transient rise in aspartate transaminase |
OAE:0002288
|
|
anaemia |
OAE:0000287
|
|
chronic hepatitis B |
OAE:0006582
|
|
weight loss |
OAE:0000541
|
|
emesis |
OAE:0001003
|
|
constipation |
OAE:0000602
|
|
transient decrease in circulating lymphocytes |
OAE:0006510
|
|
lymphocytopenia |
OAE:0001152
|
|
pain |
OAE:0000374
|
|
itching |
OAE:0007205
|
|
redness |
OAE:0002121
|
|
swelling |
OAE:0009307
|
|
induration |
OAE:0002039
|
|
ulceration |
OAE:0000691
|
|
thrombosis |
OAE:0000185
|
|
thrombocytopenia |
OAE:0001448
|
|
positive for anti-PF4 antibodies |
|
|
injection site pain |
OAE:0000369
|
|
injection-site erythema |
OAE:0000644
|
|
injection-site discomfort |
OAE:0009087
|
|
irritation |
OAE:0002023
|
|
cutaneous eruption |
OAE:0002102
|
|
pyrexia |
OAE:0000642
|
|
constitutional and dermatologic symptoms |
|
|
injection site reaction |
OAE:0000366
|
|
skin flare |
OAE:0002571
|
|
Wound infection |
OAE:0003305
|
|
herpes zoster |
OAE:0009010
|
|
Lymphopenia |
OAE:0001154
|
|
proteinuria |
OAE:0002672
|
|
hematuria |
OAE:0000619
|
|
ulcerations |
OAE:0000691
|
|
low-grade fever |
OAE:0000639
|
|
local erythema |
OAE:0000645
|
|
local swelling |
OAE:0001136
|
|
transient neutropenia |
OAE:0001217
|
|
pain in injection sites |
OAE:0000369
|
|
Erythema in injection sites |
OAE:0000645
|
|
malaise |
OAE:0000390
|
|
headach |
OAE:0000377
|
|
Adrenal insufficiency |
OAE:0003255
|
|
Hyperthyroidism |
OAE:0001977
|
|
Hypothyroidism |
OAE:0001063
|
|
Lipase increased |
OAE:0001133
|
|
increased protein in urine |
OAE:0002000
|
|
TST site reaction |
|
|
increased international normalized ratio (INR) |
OAE:0002088
|
|
local skin inflammation |
OAE:0008899
|
|
hematoma |
OAE:0000650
|
|
injection site reactions |
OAE:0000366
|
|
arthralgias |
OAE:0000385
|
|
pruritus |
OAE:0000373
|
|
moderate myalgia |
OAE:0000375
|
|
moderate injection site pain |
OAE:0000369
|
|
Cytokine release syndrome |
OAE:0000854
|
|
localized edema |
OAE:0001139
|
|
vomiting |
OAE:0000601
|
|
blood disorders |
OAE:0000731
|
|
lymphatic system disorders |
OAE:0006704
|
|
cancer pain |
|
|
anemia |
OAE:0000550
|
|
hypertension |
OAE:0000403
|
|
back pain |
OAE:0000414
|
|
elevated AST |
|
|
elevated gamma-glutamyl transferase (GGT) |
OAE:0000964
|
|
elevated alkaline phosphatase (ALP) |
OAE:0000720
|
|
dermatological reactions at injection sites |
|
|
stomatitis |
OAE:0000608
|
|
contusion |
OAE:0000019
|
|
fall |
OAE:0000939
|
|
febrile neutropenia |
OAE:0000943
|
|
pneumonia |
OAE:0000647
|
|
blood creatine phosphokinase increase |
OAE:0000529
|
|
significant differences in the genotype distribution were found in subjects with high levels of antibodies. |
|
|
significant differences in the genotype distribution were found in subjects with high levels of antibodies.In subjects with low levels of antibodies, found significant differences. |
|
|
low responsiveness to influenza vaccine in males |
|
|
lower response to influenza vaccine |
|
|
transient lymphopenia |
OAE:0001154
|
|
flu-like symptoms temporally related to vaccination |
OAE:0000399
|
|
arthralgia |
OAE:0000385
|
|
decreased lymphocyte count |
OAE:0001149
|
|
asymptomatic transient elevations in autoimmune serologies |
|
|
vaccine induced thrombotic throm bocytopenia (VITT) |
OAE:0002116
|
|
antibody immune response |
OAE:0000477
|
|
transient injection site pain |
OAE:0000369
|
|
decreased hemoglobin |
OAE:0001023
|
|
CPK |
OAE:0003448
|
|
skin ulceration |
OAE:0000691
|
|
autoimmune disorders |
OAE:0002437
|
|
elevations of rheumatoid factor (10C) or ANA (7C, 15C) |
OAE:0002222
|
|
grade 3 toxicities |
OAE:0001804
|
|
hospitalizations |
OAE:0000634
|
|
neuropathy |
OAE:0000418
|
|
neuropathic pain |
OAE:0004679
|
|
ophthalmoplegia |
OAE:0004265
|
|
capillary leak syndrome |
OAE:0000775
|
|
Anti-leucine rich glioma inactivated 1 autoimmune encephalitis |
|
|
Vaccine-induced thrombotic thrombocytopenia |
OAE:0001148
|
|
Injection site |
OAE:0000336
|
|
Artralgia |
|
|
Sore nipple |
OAE:0000538
|
|
Dry skin |
OAE:0000894
|
|
Cough |
OAE:0000398
|
|
Dermatitis |
OAE:0000086
|
|
Swelling of bursa olecrani |
|
|
induced immune thrombotic thrombocytopenia |
OAE:0001148
|
|
tenderness |
OAE:0002038
|
|
elevated creatinine kinase |
|
|
delayed neurobehavioral impairments |
|
|
reaction at the site of inoculation |
OAE:0000336
|
|
asthenia |
OAE:0000382
|
|
local reactions |
OAE:0000336
|
|
MMR-related febrile seizures |
OAE:0004366
|
|
epilepsy syndromes |
OAE:0005070
|
|
genetic epilepsy with febrile seizures plus (GEFS+) |
OAE:0004366
|
|
Dravet syndrome |
|
|
febrile seizures |
OAE:0004366
|
|
autoimmune diseases |
OAE:0006723
|
|
multiple sclerosis |
OAE:0000481
|
|
narcolepsy |
OAE:0001524
|
|
systemic AEs |
|
|
impaired humoral immunity/ antibody deficiency disorders and recurrent infections |
|
|
higher mumps-specific lymphoproliferation |
OAE:0004378
|
|
lower mumps-specific lymphoproliferation |
OAE:0004378
|
|
localized rash |
OAE:0004379
|
|
generalized rash |
OAE:0001357
|
|
lymphadenopathy |
OAE:0001147
|
|
atopic dermatitis (AD) associated with eczema vaccinatum (EV) from increased vaccubua virus replication and decreased LL-37 |
|
|
higher lymphoproliferative responses |
OAE:0004378
|
|
low antibody |
|
|
lymphoproliferative responses |
OAE:0004378
|
|
increased susceptibility to mycobacterial infections (BCG and NTM infection), may account for tuberculosis |
|
|
viscerotropic adverse events |
OAE:0004386
|
|
autoimmune disease (GBS, RA, SLE, ITP) |
OAE:0006722
|
|
encephalopathy |
OAE:0000494
|
|
Guillain-Barré syndrome (GBS) |
OAE:0000429
|
|
genetic risk factor for development of GBS in patients with preceding infection |
|
|
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) |
OAE:0002075
|
|
hereditary neuropathy with liability to pressure palsies (HNPP) |
OAE:0004380
|
|
immune thrombocytopenic purpura (ITP) |
OAE:0006466
|
|
systemic lupus erythematosus (SLE) |
OAE:0001856
|
|
autoimmune |
|
|
chronic inflammatory disorders |
OAE:0002075
|
|
psoriasis |
OAE:0000238
|
|
celiac disease |
|
|
Primary Sjogren’s syndrome |
|
|
C2-deficiency-SLE |
|
|
lupus nephropathy |
OAE:0006960
|
|
Sjogren’s syndrome (SS) |
OAE:0001908
|
|
juvenile rheumatoid arthritis (RA) |
OAE:0000475
|
|
autoimmunity diseases |
|
|
Adjuvant-induced arthritis (AIA) |
|
|
urinary tract diseases |
OAE:0005606
|
|
fever |
OAE:0000361
|
|
Inflammatory-related AE |
|
|
overstimulation |
|
|
understimulation of the inflammatory response |
|
|
localized rash |
OAE:0004379
|
|
XLA |
OAE:0004385
|
|
combined immunodeficiency (CID) |
OAE:0002404
|
|
rheumatoid arthritis (RA) |
OAE:0000475
|
|
severe myoclonic epilepsy of infancy (SMEI) and borderline SMEI |
OAE:0004383
|
|
120 out of 2,000 ducks died |
|
|
increase (12%) in IFN-γ ELISPOT responses |
|
|
increase in IFN-γ ELISPOT and antibody responses |
|
|
augmented susceptibility to fever |
OAE:0000361
|
|
eczema vaccinatum ( diffuse allergic skin inflammation) |
OAE:0009021
|
|
hepatitis B virus infection |
OAE:0006625
|
|
HIV-1 infection |
OAE:0002509
|
|
type 1 diabetes |
OAE:0009330
|
|
B. pertussis |
OAE:0004370
|
|
rubella infection |
OAE:0004381
|
|
measles |
OAE:0001911
|
